Modified Vaccinia Ankara virus variant
AssigneeBavarian Nordic A/S
InventorsPaul Chaplin, Paul Howley, Christine Meisinger-Henschel
Life of this patent
Estimating the term…
Abstract
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
Claims16
A method for inducing an immune response in a human patient comprising:
- (a) administering to the patient a priming inoculation of an effective amount of MVA-BN virus or derivative thereof, wherein the MVA-BN virus or derivative thereof is characterized by reproductive replication in vitro in chicken embryo fibroblasts and by being non-replicative in vitro in human cell lines selected from the human keratinocyte cell line HaCaT, the human embryo kidney cell line 293, the human bone osteosarcoma cell line 143B, and the human cervix adenocarcinoma cell line HeLa;
- and
- (b) administering to the patient a boosting inoculation of an effective amount of the MVA-BN virus or derivative thereof.
A method for inducing an immune response in a mammal comprising:
- (a) administering to the mammal a priming inoculation of an effective amount of MVA-BN virus or derivative thereof, wherein the MVA-BN virus or derivative thereof is characterized by reproductive replication in vitro in chicken embryo fibroblasts and by being non-replicative in vitro in human cell lines selected from the human keratinocyte cell line HaCaT, the human embryo kidney cell line 293, the human bone osteosarcoma cell line 143B, and the human cervix adenocarcinoma cell line HeLa;
- and
- (b) administering to the mammal a boosting inoculation of an effective amount of the MVA-BN virus or derivative thereof.
Dependencies are inferred from the claim text.